维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

15篇 您的检索式：作者名="Bittoni"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	5-fluorouracil pharmacogenomics: still rocking after all these years?显示文摘	Mario Scartozzi Elena Maccaroni Riccardo Giampieri Mirco Pistelli Alessandro Bittoni Michela Del Prete Rossana Berardi Stefano Cascinu	2011	Pharmacogenomics2011，，2：	1
	2	Chemotherapy for locally advanced and metastatic gastric cancer: state of the art and future perspectives显示文摘	Bittoni A Maccaroni E Seartozzi M	2010	Eur Rev Med Pharmacol Sci2010，14，4：	1
	3	Chemotherapy for locally advanced and metastatic gastric cancer:state of the art and future perapectives显示文摘	Bittoni A Maccaroni E Scartozzi M	2010	Eur Rev Med Pharmacol Sci2010，14，2：	1
	4	Prospective evaluation of C-reactive protein, smoking and lung cancer death in the Third National Health and Nutrition Examination Survey显示文摘	Bittoni MA Foeht BC Clinton SK	2015	Int J Oneol2015，47，4：	1
	5	Chemotherapy for locally advanced and metastatic gastric cancer:State of the art and future perspectives 显示文摘	Bittoni A Maccaroni E Scartozzi M	2010	Eur Rev Med Pharmacol Sci2010，14，4：	1
	6	Chemotherapy for lo- cally advanced and metastatic gastric cancer:state of the art and future perspectives显示文摘	Bittoni A Maccaroni E Scartozzi M	2010	Eur Rev Med Pharmacol Sci2010，14，：	1
	7	Toll like receptors and pancreatic diseases: From a pathogenetic mechanism to a therapeutic target显示文摘	Matteo Santoni Kalliopi Andrikou Valeria Sotte Alessandro Bittoni Andrea Lanese Chiara Pellei Francesco Piva Alessandro Conti Massimo Nabissi Giorgio Santoni Stefano Cascinu	2015	Cancer Treatment Reviews2015，，7：	1
	8	Chemotherapy for locallyadvanced and metastatic gastric cancer : state of the art and futureperspectives 显示文摘	Bittoni A Maccaroni E Scartozzi M	2010	Eur Rev Med Pharmacol Sci2010，14，4：	1
	9	Cascinu chemotherapy for locally advanced and metastatic gastric cancer:state of the art and future perspectives显示文摘	Bittoni A Maccaroni E Scartozzi M	2010	Eur Rev Med Pharmacol Sci2010，14，4：	1
	10	5-fluorouracil pharmacogenomics: still rocking after all these years?显示文摘	Mario Scartozzi Elena Maccaroni Riccardo Giampieri Mirco Pistelli Alessandro Bittoni Michela Del Prete Rossana Berardi Stefano Cascinu	2011	Pharmacogenomics2011，，2：	1
	11	Chemotherapy for locally advanced and metaslatic gastric cancer:state of the art and futureperspective显示文摘	Bittoni A Maccaroni E Scartozzi M	2010	Eur Rev Med Pharmacol Sci2010，14，4：	1
	12	Clinicalevidence for three distinct gastric cancer subtypes : Timefor a new approach 显示文摘	Bittoni A Scartozzi M Giampieri R	2013	PLoS One2013，8，78：	1
	13	Chemotherapy for locally advanced and metastatic gastric cancer:state of the art and future perspectives显示文摘	Bittoni A Maccaroni E Scartozzi M		0，，：	1
	14	Chemotherapy for locally advanced and metastatic gastric cancer:state of the art and future perspectives显示文摘	Bittoni A Maccaroni E Scartozzi M	2010	European Review For Medical And Pharmacological Sciences2010，14，4：	1
	15	Immunotherapy in colorectal cancer treatment: actual landscape and future perspectives显示文摘Colorectal cancer(CRC)represents the second most common cancer in Europe with marked differences in prognosis and response to treatments.In the past years research showed emerging interest in genomic and immunologic fields.The clinical heterogeneity,that occurs during the pathogenesis of CRC,is driven by chromosomal alterations and defective function of DNA mismatch repair genes.CRC is classified in four consensus molecular subtypes(CMS)with different immunogenic characteristics and prognosis.CMS1 microsatellite instable(MSI)-like and CMS4,both characterized by high levels of immune infiltration,are recognized as the most immunogenic subtypes,even though functional characteristic leading to different prognosis are reported.In particular,MSI tumors have been identified as the best candidates for immunotherapy treatment and a number of studies have evaluated the efficacy of anti-programmed cell death ligand-1(PDL-1)and anti-cytotoxic T-lymphocyte-associated protein 4(CTLA4)in this setting.However,literature data show that the majority of patients with CRC have microsatellite stable(MSS)tumors and this status seems related to lower response to PDL-1/programmed cell death-1 or CTLA4 blockade.The aim of this paper is to investigate the role of immunotherapy in MSI and MSS CRC.	Alessandro Bittoni Valeria Sotte Tania Meletani Luca Cantini Riccardo Giampieri Rossana Berardi	2018	Journal of Cancer Metastasis and Treatment2018，4，1：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费